Analysis of intratumoral heterogeneity and amplification status in breast carcinomas with equivocal (2+) HER-2 immunostaining

American Journal of Clinical Pathology

Volumn 124, Issue 2, 2005, Pages 273-281

  Lewis, Jason T ^a   Ketterling, Rhett P ^a   Halling, Kevin C ^a   Reynolds, Carol ^a   Jenkins, Robert B ^a   Visscher, Daniel W ^a,b  

^a MAYO CLINIC   (United States)

^b NONE   (United States)

Author keywords

Amplification; Breast carcinoma; HER 2; Immunohistochemistry

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME;

EID: 23044475881     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/J9VXABUGKC4Y07DL     Document Type: Article

References (34)

1. Jacobs TW, Gown AM, Yaziji H, et al. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol. 1999;17:1974-1982.
2. Bankfalvi A, Simon R, Brandt B, et al. Comparative methodological analysis of erbB-2/HER-2 gene dosage, chromosomal copy number and protein overexpression in breast carcinoma tissues for diagnostic use. Histopathology. 2000;37:411-419.
3. Hoang MP, Sahin AA, Ordonez NG, et al. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol. 2000;113:852-859.
4. Birner P, Oberhuber G, Stani J, et al. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res. 2001;7:1669-1675.
5. Lebeau A, Deimling D, Kaltz C, et al. HER-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol. 2001;19:354-363.
6. Tsuda H, Akiyama F, Terasaki H, et al. Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma: interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression. Cancer. 2001;92:2965-2974.
7. McCormick SR, Lillemoe TJ, Beneke J, et al. HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of Hercep Test and Path Vysion commercial assays. Am J Clin Pathol. 2002;117:935-943.
8. Gancberg D, Di Leo A, Cardoso F, et al. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol. 2002;13:1036-1043.
9. Bilous M, Ades C, Armes J, et al. Predicting the HER2 status of breast cancer from basic histopathology data: an analysis of 1500 breast cancers as part of the HER2000 International Study. Breast. 2003;12:92-98.
10. Hercep Test for the Autostainer [package insert]. Carpinteria, CA: DAKO; 2003.
11. Ridolfi R, Jamehdor MR, Arber JM. HER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach. Mod Pathol. 2000;13:866-873.
12. Tubbs RR, Pettay JD, Roche PC, et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol. 2001;19:2714-2721.
13. Yeh IT. Measuring HER-2 in breast cancer: immunohistochemistry, FISH, or ELISA? Am J Clin Pathol. 2002;117 suppl:S26-S35.
14. Ogura H, Akiyama F, Kasumi F, et al. Evaluation of HER-2 status in breast carcinoma by fluorescence in situ hybridization and immunohistochemistry. Breast Cancer. 2003;10:234-240.
15. Zhang D, Salto-Tellez M, Do E, et al. Evaluation of HER-2/neu oncogene status in breast tumors on tissue microarrays. Hum Pathol. 2003;34:362-368.
16. Mrhalova M, Kodet R, Kalinova M, et al. Relative quantification of ERBB2 mRNA in invasive duct carcinoma of the breast: correlation with ERBB-2 protein expression and ERBB2 gene copy number. Pathol Res Pract. 2003;199:453-461.
17. Battifora H, Kopinski M. The influence of protease digestion and duration of fixation on the immunostaining of keratins: a comparison of formalin and ethanol fixation. J Histochem Cytochem. 1986;34:1095-1100.
18. Penault LF, Adelaide J, Houvenaeghel G, et al. Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation. J Pathol. 1994;173:65-75.
19. van Diest PJ, van Dam P, Henzen-Logmans SC, et al, for the European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group. A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. J Clin Pathol. 1997;50:801-804.
20. Thomson TA, Hayes MM, Spinelli JJ, et al. HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol. 2001;14:1079-1086.
21. Fujii H, Marsh C, Cairns P, et al. Genetic divergence in the clonal evolution of breast cancer. Cancer Res. 1996;56:1493-1497.
22. Perez EA, Roche PC, Jenkins RB, et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc. 2002;77:148-154.
23. Pauletti G, Godolphin W, Press MF, et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996;13:63-72.
24. Cardoso F, Di Leo A, Larsimont D, et al. Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. Ann Oncol. 2001;12:615-620.
25. Glockner S, Buurman H, Kleeberger W, et al. Marked intratumoral heterogeneity of c-myc and cyclinD1 but not of c-erbB2 amplification in breast cancer. Lab Invest. 2002;82:1419-1426.
26. Sekido Y, Umemura S, Takekoshi S, et al. Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation. Int J Oncol. 2003;22:1225-1232.
27. Wang S, Saboorian MH, Frenkel EP, et al. Assessment of HER-2/neu status in breast cancer: Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am J Clin Pathol 2001;116:495-503.
28. Szollosi J, Balazs M, Feuerstein BG, et al. ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer. Cancer Res. 1995;55:5400-5407.
29. Miller DV, Jenkins RB, Lingle WL, et al. Focal HER2/neu amplified clones partially account for discordance between immunohistochemistry and fluorescence in-situ hybridization results: data from NCCTG N9831 Intergroup Adjuvant Trial [abstract]. J Clin Oncol. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004;22(14S):568.
30. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707-712.
31. Ross JS, Fletcher JA, Linette GP, et al. The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist. 2003;8:307-325.
32. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719-726.
33. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000;18:3651-3664.
34. Hsu CY, Ho DM, Yang CF, et al. Interobserver reproducibility of HER-2/neu protein overexpression in invasive breast carcinoma using the DAKO Hercep Test. Am J Clin Pathol. 2002;118:693-698.